T-regulatory lymphocytes in peripheral blood of gastric and colorectal cancer patients

Table 3 Mean (SD) proportion of CD4⁺CD25⁺Foxp3⁺ cells in the CD4⁺ population (percentage)

	Colorectal cancer	P1	Gastric cancer	P1	Overall	P1
Overall	2.18 (1.79)		2.01 (1.56)	0.760
Sex		0.332		0.455		0.820
Male	2.31 (1.68)		1.89 (1.62)		2.12 (1.65)
Female	1.98 (2.01)		2.18 (1.51)		2.08 (1.75)
Age (yr)		0.456		0.610		0.777
≤ 65	2.32 (1.58)		1.88 (1.63)		2.13 (1.59)
> 65	2.05 (2.00)		2.11 (1.54)		2.08 (1.76)
Tumor grade		0.477		1.000		0.758
1	2.46 (1.72)		0		2.19 (1.80)
2 or 3	2.11 (1.90)		2.10 (1.36)		2.09 (1.80)
Lymph node metastases		0.316		0.388		0.172
No	2.60 (2.13)		2.73 (2.04)		2.63 (2.07)
Yes	1.73 (1.25)		1.94 (1.53)		1.85 (1.41)
Distant metastases		0.818		0.854		0.798
No	2.23 (1.98)		1.95 (1.72)		2.14 (1.88)
Yes	2.03 (1.09)		2.05 (1.49)		2.04 (1.36)
Stage		0.254		0.423		0.138
I or II	2.56 (2.22)		2.75 (2.35)		2.59 (2.18)
III or IV	1.66 (1.33)		1.66 (1.32)		1.66 (1.31)

¹Mann-Whitney U test. The Tregs/CD4⁺ ratio in healthy volunteers group was 2.1%, and this was equal to that observed in gastric cancer patients.